Zentalis Pharmaceuticals, Inc ZNTL Stock Price Today, Quote & News

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. SVB Securities analyst Andrew Berens maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) today and set a price target of $27.00. The company’s shares closed yesterday at $18.39.According to TipRank… Zentalis Pharmaceuticals has a 1 year low of $15.55 and a 1 year high of $52.85.

• The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.
• It’s calculated by dividing the current share price by the earnings per share .
• The firm has a 50 day moving average of $19.20 and a two-hundred day moving average of $20.79.
• This means that share ownership of 13D/G filings and 13F filings are oftentimes not directly comparable, so we present them separately.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds. The price-earnings ratio is a company’s share price to the company’s Earnings per Share. The ratio is used for evaluating companies and to find out whether they are overvalued or undervalued. The price-to-book ratio is a company’s current market price to its Book Value. Traditionally, any value under 1.0 is considered a good P/B value, indicating a potentially undervalued stock. We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer.

Finally, Evergreen Capital Management LLC acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth about $366,000. A number of other institutional investors and hedge funds have also recently modified their holdings of ZNTL. State Street Corp boosted its stake in Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company’s stock valued at $87,665,000 after acquiring an additional 1,039,294 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 85.4% in the 3rd quarter.

Quotes & News

The hyperinflation: definition, causes, effects, examples twelve-month price prediction for Zentalis Pharmaceuticals is $43.44 with a high price target of $55.00 and a low price target of $27.00. Several equities research analysts have recently commented on ZNTL shares. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, March 2nd. Stifel Nicolaus reduced their price target on shares of Zentalis Pharmaceuticals from $55.00 to $46.00 in a research report on Wednesday, March 15th. Zentalis Pharmaceuticals Inc.’s market cap currently stands at around $1.03 billion. Analysts project the company’s earnings per share to be -$0.97, which has seen fiscal year 2023 EPS growth forecast to increase to -$4.08 and about -$4.22 for fiscal year 2024.

While the effectiveness of this highly sought-after metric is questionable, the posi… Wells Fargo, on the other hand, stated in their research note that they expect to see ZNTL reach a price target of $67. The rating they have provided for ZNTL stocks is “Overweight” according to the report published on April 06th, 2022. The stock of Zentalis Pharmaceuticals Inc. has seen a -7.75% decrease in the past week, with a -9.63% drop in the past month, and a -8.53% decrease in the past quarter.

Zentalis Pharmaceuticals Consensus Rating and Price Target (

Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument. The company’s average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings. During the last 5 trading sessions, ZNTL fell by -7.70%, which changed the moving average for the period of 200-days by -35.87% in comparison to the 20-day moving average, which settled at $18.27.

According to 17 analysts, the average rating for ZNTL stock is “Buy.” The 12-month stock price forecast is $52.22, which is an increase of 199.94% from the latest price. The Fund Sentiment Score finds the stocks that are being most bought by funds. It is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average. The chart below shows how a company’s ratings by analysts have changed over time.

Financials

The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success.

• All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
• Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”.
• Finally, ExodusPoint Capital Management LP acquired a new stake in Zentalis Pharmaceuticals in the third quarter worth about $3,422,000.
• Eventide Asset Management LLC boosted its position in shares of Zentalis Pharmaceuticals by 85.4% in the 3rd quarter.

The firm’s fifty day simple moving average is $19.64 and its 200 day simple moving average is $20.93. The firm has a market capitalization of $1.06 billion, a P/E ratio of -3.95 and a beta of 1.87. Options trading entails significant risk and is not appropriate for all investors. Option investors can rapidly lose the value of their investment in a short period of time and incur permanent loss by expiration date. You need to complete an options trading application and get approval on eligible accounts. Please read the Characteristics and Risks of Standardized Options before trading options.

It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. 8 Wall Street research analysts have issued 12 month target prices for Zentalis Pharmaceuticals’ shares.

Six sponsored studies with https://1investing.in/ly first-in-class Wee1 inhibitor, ZN-c3, ongoing and continuing dose optimization work, as drug continues to show improved tolerability in initial safety data from … Sign-up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat’s FREE daily newsletter. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services.

Since then, ZNTL stock has decreased by 13.6% and is now trading at $17.41. In the past three months, Zentalis Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $663,560.00 in company stock. Zentalis Pharmaceuticals has a short interest ratio (“days to cover”) of 14.5, which indicates bearish sentiment.

Its specialists are interested in stocks that have been undervalued by different reasons. They are trying to find them, count their potential and bring them to their clients. Bunker Kevin D., the Chief Scientific Officer of Zentalis Pharmaceuticals Inc., sale 6,500 shares at $19.98 during a trade that took place back on Feb 14, which means that Bunker Kevin D.

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. Zentalis Pharmaceuticals set terms of its initial public offering, in which the biopharmaceutical company developing cancer treatments is expected to raise up to $137.7 million. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.98.

Separately, ZNTL on Monday priced its underwritten offering of 10.3M shares at an offering price of $19.38/share for total gross proceeds of ~$200.2M. No content on the Webull Financial LLC website shall be considered as a recommendation or solicitation for the purchase or sale of securities, options, or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.

Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.44. 8 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Zentalis Pharmaceuticals in the last twelve months. The consensus among Wall Street analysts is that investors should “buy” ZNTL shares. Hedge funds and other institutional investors have recently added to or reduced their stakes in the business.

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haemonetics (HAE – Research Report), Alcon (ALC – Research Report) and Zentalis Pharmaceuticals (ZNTL – Research Report).